Genertec Universal Medical Group Company Limited
UMTAF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.85 | 4.22 | 1.57 | 0.48 |
| FCF Yield | 45.51% | 17.34% | -18.67% | -15.92% |
| EV / EBITDA | 17.09 | 16.53 | 17.96 | 18.54 |
| Quality | ||||
| ROIC | 12.28% | 7.74% | 10.12% | 7.09% |
| Gross Margin | 32.35% | 35.79% | 40.26% | 39.74% |
| Cash Conversion Ratio | 1.74 | 1.05 | -0.72 | -0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.94% | 11.95% | 12.35% | 24.27% |
| Free Cash Flow Growth | 182.74% | 181.15% | -30.04% | 32.43% |
| Safety | ||||
| Net Debt / EBITDA | 14.45 | 13.91 | 14.81 | 15.31 |
| Interest Coverage | 302.60 | 79.25 | 90.98 | 74.67 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -120.16 | -112.77 | -71.02 | -63.81 |